Comparing BioLargo (BLGO) and Its Rivals

BioLargo (NASDAQ:BLGO) is one of 33 public companies in the “Chemicals & allied products” industry, but how does it contrast to its peers? We will compare BioLargo to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.

Volatility & Risk

BioLargo has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, suggesting that their average share price is 81% more volatile than the S&P 500.

Valuation and Earnings

This table compares BioLargo and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.12
BioLargo Competitors	$6.84 billion	$211.64 million	67.91

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-591.84%	5.15%	-0.65%

Analyst Recommendations

This is a breakdown of current recommendations for BioLargo and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1250	1568	44	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 13.47%. Given BioLargo’s peers higher probable upside, analysts clearly believe BioLargo has less favorable growth aspects than its peers.

Summary

BioLargo peers beat BioLargo on 8 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.